Left Atrial Function in Patients With Diffuse Large B‐Cell Lymphoma Treated With R‐CHOP Chemotherapy Regimen: A Speckle Tracking Echocardiographic Study
Echocardiography · 2025
DOI: 10.1111/echo.70339 ↗At a glance
Journal article in Echocardiography, 2025. Written by Baozhen Wang and 10 co-authors. Institution: Department of Ultrasound, Cangzhou People's Hospital, Cangzhou, China. Major MEDLINE topics: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Echocardiography, Heart Atria. Cited 1 times so far (Crossref); 36 references. Funded by: Cangzhou Key Research & Development Program.
Topics: Onkologische Pflege
Abstract (original language)
Objective
This study aimed to determine whether left atrial (LA) strain can identify early alterations in LA function in diffuse large B‐cell lymphoma (DLBCL) patients treated with R‐CHOP chemotherapy regimen and whether these alterations can prospectively predict the subsequent development of cancer therapy–related cardiac dysfunction (CTRCD).
Methods
DLBCL patients scheduled to receive the R‐CHOP regimen were prospectively recruited for this study. Echocardiography was performed at T0 (pre‐chemotherapy), T1 (after the third cycle), T2 (end of 6–8 cycles), and T3 (1‐year post‐T2). Left ventricular global longitudinal strain (LV GLS), LA reservoir strain (LASr), LA conduit strain (LAScd), LA contraction strain (LASct), and LA stiffness index (LASI) were calculated using speckle tracking echocardiography (STE). Patients were divided into CTRCD and non‐CTRCD groups based on a > 15% reduction in LV GLS.
Results
Seventeen patients (23.6%) developed to CTRCD after chemotherapy. Patients who developed CTRCD were relatively older (67 [57–71] vs. 60 [49–68], p < 0.05). A significant deterioration in LASr, LAScd, and LASI at T1 persisted throughout the follow‐up period. Relative changes in LASr (≥ 23.4%) and LASI (≥ 20.0%) were robust predictors of subsequent CTRCD development. The LASr > 35% criterion in the validation cohort demonstrated substantial agreement with the 2016 ASE guidelines.
Conclusion
LASr and LASI effectively identify early alterations in LA function in DLBCL patients. Relative changes in LASr and LASI are robust predictors of subsequent CTRCD development.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Ultrasound, Cangzhou People's Hospital, Cangzhou, China.
- Medical Imaging Center, Cangzhou People's Hospital, Cangzhou, China.
- Department of Oncology, Cangzhou People's Hospital, Cangzhou, China.
ORCID profiles: Baozhen Wang
Funding
- Cangzhou Key Research & Development Program
Cite
APA
Wang, B., Hao, X., Yu, Y., Cao, W., Huang, D., Xie, G., Yang, S., Zhao, H., Zhang, Y., Hao, H., & Zhang, Y. (2025). Left Atrial Function in Patients With Diffuse Large B‐Cell Lymphoma Treated With R‐CHOP Chemotherapy Regimen: A Speckle Tracking Echocardiographic Study. Echocardiography. https://doi.org/10.1111/echo.70339
Vancouver
Wang B, Hao X, Yu Y, Cao W, Huang D, Xie G, et al. Left Atrial Function in Patients With Diffuse Large B‐Cell Lymphoma Treated With R‐CHOP Chemotherapy Regimen: A Speckle Tracking Echocardiographic Study. Echocardiography. 2025. doi:10.1111/echo.70339
BibTeX
@article{Wang2025,
author = {Wang, Baozhen and Hao, Xiaoyi and Yu, Yang and Cao, Wenwen and Huang, Dangui and Xie, Guangping and Yang, Shan and Zhao, Hong and Zhang, Ying and Hao, Hui and Zhang, Yaxin},
title = {Left Atrial Function in Patients With Diffuse Large B‐Cell Lymphoma Treated With R‐CHOP Chemotherapy Regimen: A Speckle Tracking Echocardiographic Study},
journal = {Echocardiography},
year = {2025},
doi = {10.1111/echo.70339}
}
EUVIMED